# Ciclesonide

## Alvesco Inhaler 160mcg/puff, 60 puffs

| TAH Drug Code      | [EALV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=EALV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Persistent asthma in patients aged four and above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Initial, 80 mcg oral inhalation twice daily; higher doses may provide additional control in patients who do no respond adequately after 4 weeks of treatment; MAX, 320 mcg twice daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to ciclesonide or any component of the product. Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive intervention.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Common: Arthralgia (oral inhalation, 0.9-3.5%), Backache (oral inhalation, 0.6-3.1%), Headache (intranasal, up to 3.1% ; oral inhalation, 4.9-11%), Otalgia (intranasal, 2.2%), Bleeding from nose (intranasal, 2.9-11.4%), Nasal congestion (oral inhalation, 1.8-5.5%), Nasopharyngitis (intranasal, 3.7%; oral inhalation, 7-10.5%), Pain in throat (oral inhalation, 2.4-4.7%), Sinusitis (oral inhalation, 3.1-5.5%), Upper respiratory infection (intranasal, at least 2% ; oral inhalation, 4.1-8.7%), Pain, In extremity (oral inhalation, 0.3-3.1%) Serious: Adrenal insufficiency, Type 2 diabetes mellitus, Hypersensitivity reaction (rare), Cataract, Glaucoma, Raised intraocular pressure, Asthma, acute (6%), Bronchospasm |
| Pregnancy          | Compatible â€“ Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

